|1.||Boyle, David L: 2 articles (01/2007 - 02/2004)|
|2.||Hammaker, Deepa R: 2 articles (01/2007 - 02/2004)|
|3.||Firestein, Gary S: 2 articles (01/2007 - 02/2004)|
|4.||Dumas, Karine: 1 article (07/2015)|
|5.||Vergoni, Bastien: 1 article (07/2015)|
|6.||Cormont, Mireille: 1 article (07/2015)|
|7.||Alemany, Susana: 1 article (07/2015)|
|8.||Tanti, Jean-François: 1 article (07/2015)|
|9.||Berthou, Flavien: 1 article (07/2015)|
|10.||Ceppo, Franck: 1 article (07/2015)|
04/01/2011 - "Recent clinical trials with selective inhibitors of the BRAF and MEK kinases have shown promising results in patients with tumors harboring BRAF V600 mutations. "
08/23/2012 - "Analysis of patient tumors suggests that multiple MAP3 kinases (MAP3Ks) are critical for growth and metastasis of cancer cells. "
08/23/2012 - "Defining MAP3 kinases required for MDA-MB-231 cell tumor growth and metastasis."
11/01/2010 - "Apoptosis signal regulating kinase-1 (ASK1) is a MAP kinase kinase kinase implicated in cancer, cardiovascular and neurodegenerative diseases. "
07/01/2015 - "Here, we demonstrated that the MAP kinase kinase kinase tumor progression locus 2 (Tpl2) controls COX-2 expression and PGE2 secretion in adipocytes in response to different inflammatory mediators. "
|2.||Melanoma (Melanoma, Malignant)
09/01/2011 - "Inhibitors of B-Raf and MEK kinases hold promise for the management of cutaneous melanomas harboring BRAF mutations. "
12/01/2014 - "Treatment of BRAFV600E-mutant melanoma by small molecule inhibitors that target BRAFV600E or MEK kinases is increasingly used in clinical practice and significantly improve patient outcome. "
04/03/2014 - "Treatment of BRAF(V600E) mutant melanoma by small molecule drugs that target the BRAF or MEK kinases can be effective, but resistance develops invariably. "
02/01/2012 - "Focusing on the mitogen-activated protein (MAP) kinase kinase kinase (MAP3K) family, we found that 24% of melanoma cell lines have mutations in the protein-coding regions of either MAP3K5 or MAP3K9. "
02/01/2004 - "Regulation of c-Jun N-terminal kinase by MEKK-2 and mitogen-activated protein kinase kinase kinases in rheumatoid arthritis."
01/01/2007 - "These studies were designed to assess the hierarchy of upstream MEKKs, MEKK1, MEKK2, MEKK3, and transforming growth factor-beta activated kinase (TAK)1, in rheumatoid arthritis (RA). "
01/07/1999 - "In this study, we found that the DNA-damaging agent cisplatin (cDDP) activated MAP kinase kinase kinase ASK1 and subsequent downstream subgroups of MAP kinase kinase, SEK1 (or MKK4) and MKK3/MKK6, which in turn activated c-Jun N-terminal kinase 1/stress-activated protein kinase (JNK1/SAPK) and p38 MAP kinase prior to caspase family protease activation and the onset of apoptosis in human ovarian carcinoma (OVCAR-3) and human kidney (293T) cells. "
|5.||Cardiomegaly (Heart Hypertrophy)
02/01/2006 - "Transforming growth factor beta (TGFbeta)-activated kinase 1 (TAK1) is a MAP kinase kinase kinase involved in numerous signalling pathways and is strongly implicated in cardiac hypertrophy and heart failure. "
12/01/2005 - "The mitogen-activated kinase kinases (MEK)-extracellular signal-regulated kinases (ERK) signaling pathway is activated by agonists like catecholamines or endothelin-1 (ET-1) and has been implicated in cardiac pathology, such as the progression from cardiac hypertrophy to failure. "
07/01/1995 - "To clarify the signal transduction pathways from external mechanical stress to nuclear gene expression in stretch-induced cardiac hypertrophy, we have elucidated protein kinase cascade of phosphorylation by examining the time course of activation of MAP kinase kinase kinases (MAPKKKs), MAP kinase kinase (MAPKK), MAPKs, and p90rsk in neonatal rat cardiac myocytes. "
|2.||Mitogen-Activated Protein Kinase Kinases (MEKs)
|3.||Transforming Growth Factor beta (TGF-beta)
|4.||Mitogen-Activated Protein Kinase 8
|5.||p38 Mitogen-Activated Protein Kinases
|6.||DNA (Deoxyribonucleic Acid)
|8.||MAP Kinase Kinase Kinases (MAP Kinase Kinase Kinase)
|9.||Protein Kinases (Protein Kinase)